AZN vs MIRM

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

MIRM exhibits severe fundamental weakness with a Piotroski F-Score of 2/9, indicating poor financial health and operational inefficiency. While the company shows impressive revenue growth of 49.8% and strong gross margins, this is offset by a lack of profitability and an extremely stretched valuation (P/B of 15.91). There is a stark divergence between the 'strong_buy' analyst consensus and the bearish reality of aggressive insider selling by the CEO, CFO, and President. The combination of a bearish technical trend (10/100) and deteriorating deterministic scores suggests the current price is speculative and unsupported by fundamentals.